Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden | SpringerLink
Spinraza Can Restore Motor Function in Children With Late-Onset SMA, Study Finds
Higher-dose Spinraza SMA Trial Now Enrolls After No Safety Issues Found
Biogen Announces New Spinraza Data Ahead of Presentation | BioSpace
Ionis's Spinraza Still Bests Novartis's Zolgensma (NYSE:NVS) | Seeking Alpha
Later-Onset SMA (Types 2 & 3)| SPINRAZA® (nusinersen)
From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1 - Pediatric Neurology
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy | NEJM
SMA treatment: Novartis and Biogen face lost market opportunities
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study - The Lancet
Interim results: Infantile-onset SMA | SPINRAZA® (nusinersen) HCP
Spinraza – Canada – final drug review | High, apple pie, in the sky, hopes
Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy | Nature Neuroscience
Risdiplam trials: exciting early results in Firefish – TreatSMA
An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials | SpringerLink
Drug Trials Snapshots: SPINRAZA | FDA
SMA patients can switch from Spinraza to Zolgensma' < Hospital < 기사본문 - KBR
SPINRAZA® (nusinersen) Safety Profile | HCP
Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients
Later-Onset SPINRAZA® (nusinersen) Efficacy | HCP
Threats to Spinraza are mounting, but Biogen still has cards to play | Evaluate
Spinraza (nusinersen) for the Treatment of Spinal Muscular Atrophy (SMA) - Clinical Trials Arena
Combinatorial treatment for spinal muscular atrophy - Poletti - 2020 - Journal of Neurochemistry - Wiley Online Library
Later-Onset SMA (Types 2 & 3)| SPINRAZA® (nusinersen)
Later-Onset SMA (Types 2 & 3)| SPINRAZA® (nusinersen)
Drug Trials Snapshots: SPINRAZA | FDA
